A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2017
At a glance
- Drugs S 033188 (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Registrational; Therapeutic Use
- Acronyms CAPSTONE 1
- Sponsors Shionogi
- 05 Oct 2017 Results presented in a Shionogi Media Release.
- 28 Sep 2017 According to a Shionogi media release, data will be presented at IDWeek 2017.
- 13 Sep 2017 According to a Shionogi media release, results from this trial were released at the 6th European Scientific Working Group on Influenza Conference (ESWI) 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History